Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05031806 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease
A Phase 1 study, sponsored by Xequel Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT05031806 is a Phase 1 study that has completed, run by Xequel Bio. The registered enrollment target is 30 participants.
The verdict
NCT05031806, a Phase 1 study, has completed, sponsored by Xequel Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of iNexin™ The secondary objective is to compare the efficacy of iNexin™ to Vehicle for the treatment of the signs and symptoms associated with dry eye disease.
Interventions
- DRUG iNexin™ (0.08% aCT1)
- DRUG iNexin™ (0.4% aCT1)
- DRUG iNexin™ (2.0% aCT1)
- DRUG Vehicle (eye drop formulation without aCT1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-09-28 |
| Est. Completion | 2021-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05031806
The ClinicalTrials.gov registry entry for NCT05031806 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xequel Bio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which iNexin™ (0.08% aCT1) is the first listed.
NCT05031806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05031806 about?
NCT05031806 is a clinical study titled "Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease". The primary objective of this study is to evaluate the safety and tolerability of iNexin™ The secondary objective is to compare the efficacy of iNexin™ to Vehicle for the treatment of the signs and symptoms associated with dry eye disease.
What is the current status of trial NCT05031806?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2021-09-28. Estimated completion is 2021-12-01.
What interventions are being tested in trial NCT05031806?
The interventions under investigation include: iNexin™ (0.08% aCT1) (DRUG), iNexin™ (0.4% aCT1) (DRUG), iNexin™ (2.0% aCT1) (DRUG), Vehicle (eye drop formulation without aCT1) (DRUG).
Who is sponsoring clinical trial NCT05031806?
This trial is sponsored by Xequel Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.